Results 61 to 70 of about 4,829 (180)

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia

open access: yeseJHaem
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman   +2 more
doaj   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

open access: yesTransplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford   +32 more
wiley   +1 more source

Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia

open access: yesXiehe Yixue Zazhi
Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by autoantibodies. With an increasing understanding of the immunopathogenesis of wAIHA, significant progress has been made in the development of drugs targeting different ...
WANG Qi, CHEN Miao
doaj   +1 more source

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke   +10 more
wiley   +1 more source

Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review

open access: yesHematology, Transfusion and Cell Therapy, 2022
Mohammad Ammad Ud Din   +2 more
doaj   +1 more source

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

open access: yesImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin   +92 more
wiley   +1 more source

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors

open access: yesLeukemia Research Reports
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a CD20 ...
Nkolika Nwankwo   +3 more
doaj   +1 more source

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy